Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with rheumatoid arthritis
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with rheumatoid arthritis
1 finding from 1 review
Incidence of gastroduodenal ulcers ≥ 3 mm · patients with rheumatoid arthritis
Celecoxib showed no clear difference in incidence of gastroduodenal ulcers ≥ 3 mm compared with placebo (low certainty).
1 finding from 1 review
Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Total number of withdrawals · patients with rheumatoid arthritis
Celecoxib may leads to lower total withdrawals; compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in clinical improvement: American College of Rheumatology 20%… compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with rheumatoid arthritis
1 finding from 1 review
Any adverse event · children and adolescents with chronic non‐cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse event · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbation of ulcerative colitis · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in exacerbation of ulcerative colitis compared with placebo (low certainty).
1 finding from 1 review
GI adverse events · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of dementia · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · older people with age‐related memory loss
NSAIDs (celecoxib) may leads to higher adverse events – gastrointestinal compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · older people with age‐related memory loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive decline · older people with age‐related memory loss
1 finding from 1 review